(COVID-19 Updates) SNP Genotyping and Analysis Market  Is Rapidly Increasing Worldwide in Near Future
SEATTLE, May 04, 2021, (PHARMIWEB) —
Gene-wide SNP genotyping, human SNP analysis, parentage and pedigree testing, food traceability, breed discrimination, biomarker determination and validation, pharmacogenomics, and forensics are all applications of SNP genotyping.
Launch of new products is expected to propel growth of the global SNP genotyping and analysis market over the forecast period. For instance, Natera, Inc., the developer of core SNP-based massively multiplexed PCR (mmPCR) technology, announced a new technique to boost Prospera donor-derived cell-free DNA (dd-cfDNA) transplant rejection evaluation test results in June 2020.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3972
The market’s development is projected to be hindered by an adverse reimbursement scenario. Genotyping and DNA sequencing studies vary in price from $1,000 to $3,000. Currently, insurance providers do not reimburse these disease examinations.
Rising prevalence of genetic disorders and technological innovation are two major factors is expected to drive the growth of the global SNP genotyping market during the forecast period.
The global SNP genotyping and analysis market was worth US$ 9,485.2 million in 2019, and is projected to rise at a CAGR of 21.9 percent to US$ 46,268.9 million by 2027.
The global SNP genotyping and analysis marketis estimated to account for US$ 11,553.0 Mn in terms of value in 2020 and is expected to reach US$ 46,268.9 Mn by the end of 2027.
In terms of value, SNP Microarray dominated the global SNP genotyping and analysis market in 2019, with a 37.9% share, led by Taqman Allelic Discrimination and Others, respectively. Over the forecast period, the segment’s wide range of applications is expected to support development.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3972
To increase their market share, key players in the market are concentrating on forming alliances. For instance, LGC Limited partnered with Co-Diagnostics Inc., in October 2018, a molecular diagnostics company, to test the performance of CoPrimers in multiplexed reactions when locating unique genetic traits in seed products and mutations that consists of SNP detection.
The market’s key players are also focusing on introducing new array technologies. Thermo Fisher Scientific, for instance, released the Applied Biosystems Axiom Microbiome Array in February 2018 for simultaneous identification of archaea, bacteria, fungi, protozoa, and viruses in human and non-human samples.
Major players operating in the global SNP genotyping and analysis market include, Life Technologies Corporation, PREMIER Biosoft, Thermo Fisher Scientific, LGC Limited, Fluidigm Corporation, Illumina, Inc., and Sequenom, Inc.
In February 2020, Swift Biosciences, Inc., a manufacturer of DNA and RNA library preparation kits for Next-Generation Sequencing (NGS), collaborated with LGC Limited to incorporate Swift’s targeted sequencing technology into LGC Limited’s AgBio kits and services.
Buy This Complete A Business Report:
Global SNP Genotyping and Analysis Market, By Technology:
- SNP Microarray
- Taqman Allelic Discrimination
- SNP Pyrosequencing Technologies
- Sequenom Mass-Array MALDI-TOF
Global SNP Genotyping and Analysis Market, By Application:
- Pharmaceuticals and Pharmacogenomics
- Diagnostic Research
- Agricultural Biotechnology
- Breeding and Animal Livestock
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/snp-genotyping-and-analysis-market-3240
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
- CDN Newswire